🟢 AIM ImmunoTech is trading 17.52% up in pre-market after broad U.S. patent covering Ampligen and pembrolizumab

AIM ImmunoTech is trading at $0.27, up 17.52% in pre-market trading on September 1, 2026, after announcing a broad U.S. patent for Ampligen combined with pembrolizumab in cancer treatment.

• The patent covers multiple cancer indications and expires December 20, 2039.
• Shares closed at $0.23 on August 31, when patent-driven buying reversed intraday.
• Broader markets are slightly weaker, making the company-specific patent catalyst the clearest explanation.